Compounds and methods of use thereof for treating neurodegenerative disorders
AssigneeThe Johns Hopkins University
InventorsDonald J. Zack, Derek Stuart Welsbie, Zhiyong Yang
Life of this patent
Estimating the term…
Abstract
Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.
Claims38
A method for treating or reducing the probability of developing a neurodegenerative disease, disorder, or condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, thereby treating or reducing the probability of developing the neurodegenerative disease, disorder, or condition:
A method for treating or reducing the probability of developing a neurodegenerative disease, disorder, or condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of crizotinib, KW-2449, bosutinib, axitinib, and dasatinib, thereby treating or reducing the probability of developing the neurodegenerative disease, disorder, or condition.
A method for promoting retinal ganglion cell (RGC) or photoreceptor cell survival, the method comprising contacting a RGC or photoreceptor cell with at least one compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in an amount sufficient to promote RGC or photoreceptor cell survival:
A method for identifying injury to an RGC or a photoreceptor cell, the method comprising measuring levels of dual-leucine zipper kinase (DLK) protein in the RGC or photoreceptor cell;
- and comparing the levels of DLK protein in the RGC or photoreceptor cell to the levels of DLK protein in a control RGC or photoreceptor cell;
- wherein a significant difference between the levels of DLK protein in the RGC or photoreceptor cell and the levels of DLK protein in the control RGC or photoreceptor cell is indicative of injury to the RGC or photoreceptor cell.
A method of identifying injury to an RGC or a photoreceptor cell, the method comprising measuring levels of leucine zipper-bearing kinase (LZK) protein in the RGC or photoreceptor cell;
- and comparing the levels of LZK protein in the RGC or photoreceptor cell to the levels of LZK protein in a control RGC or photoreceptor cell;
- wherein a significant difference between the levels of LZK protein in the RGC or photoreceptor cell and the levels of LZK protein in the control RGC or photoreceptor cell is indicative of injury to the RGC or photoreceptor cell.
A method of identifying injury to an RGC or a photoreceptor cell in a subject, the method comprising:
- (a) obtaining a sample from a subject;
- (b) measuring levels of dual-leucine zipper kinase (DLK) protein and/or leucine zipper-bearing kinase (LZK) protein in the sample;
- and (c) comparing the levels of DLK protein and/or LZK protein in the sample with the levels of DLK protein and/or LZK protein in a control sample;
- wherein a significant difference between the levels DLK protein and/or LZK protein in the sample and the levels of DLK protein and/or LZK protein in the control sample is indicative of injury to a RGC or photoreceptor cell in the subject.
Dependencies are inferred from the claim text.